SJALL Clinical Trials

Study goal:

To find out whether a child’s leukemia or lymphoma is low-risk, standard-risk, or high-risk. The risk category will determine the treatment the child will receive. 

Diagnosis:

Acute lymphoblastic leukemia, lymphoblastic leukemia,  mixed phenotype acute leukemia, lymphoblastic lymphoma (Non-Hodgkin lymphoma)

Age:

1-18 years

Study goal:

To compare the effects of adding inotuzumab and blinatumomab to standard chemotherapy during treatment for newly diagnosed ALL and LLy; to learn whether the length of time that inotuzumab stays in the body affects treatment success or side effects; to learn more about the biological and genetic or genomic traits that predict treatment success and toxicity in children. 

Diagnosis:

B-cell acute lymphoblastic leukemia, lymphoblastic leukemia, lymphoblastic lymphoma (Non-Hodgkin lymphoma)

Age:

1-18 years

Study goal:

To compare the effects of adding venetoclax, dasatinib, or bortezomib to standard chemotherapy for T-ALL, T-LLy, and MPAL, and to learn more about the biological and genetic or genomic traits that predict treatment success and toxicity in children.

Diagnosis:

T-cell acute lymphoblastic leukemia, T-cell lymphoblastic lymphoma, mixed phenotype acute leukemia

Age:

1-18 years